Novartis announced on Thursday that the FDA has approved a label update for secukinumab (Cosentyx) to include moderate to severe scalp psoriasis, a particularly challenging form of psoriasis to treat, and a condition that affects approximately half of patients with psoriasis.
Novartis announced on Thursday that the FDA has approved a label update for secukinumab (Cosentyx) to include moderate to severe scalp psoriasis, a particularly challenging form of psoriasis to treat, and a condition that Novartis says affects approximately half of patients with psoriasis.
The label update was based on data from the phase 3 SCALP study of secukinumab versus placebo in 102 patients with scalp psoriasis. Patients were randomized to receive either 300 mg of secukinumab or placebo at weeks 0, 1, 2, and 3, and then every 4 weeks for 12 weeks. The proportion of patients who had an Investigator’s Global Assessment scalp-only score of 0 or 1 (clear or almost clear) during the study period were 56.9% for the secukinumab arm and 5.9% for the placebo arm.
Secukinumab was the first interleukin-17A inhibitor FDA-approved to treat moderate to severe plaque psoriasis, and the label update, says Eric Hughes, global development unit head of immunology and dermatology at Novartis, “…confirms the additional value Cosentyx offers to patients who seek a treatment effective in various areas of the body…we’re proud to expand treatment possibilities of Cosentyx for an even greater number of patients."
Already this year, Novartis released data from the head-to-head CLARITY study showing that secukinumab outperformed ustekinumab (Stelara) in treating psoriasis, and announced that it is initiating the SURPASS trial, a head-to-head clinical trial of secukinumab versus adalimumab in patients with ankylosing spondylitis. Already recruiting is the EXCEED trial, yet another head-to-head trial of secukinumab versus adalimumab in patients with psoriatic arthritis.
As the originator adalimumab (Humira) moves closer to patent expiry, secukinumab’s growing body of positive data may help it to compete for a substantial share of the inflammatory disease market against an increasing number of US- and EU-approved biosimilars. Already, secukinumab has become a top earner for Novartis, with 2017 sales of $615 million across all indications—up 53% from 2016—according to Novartis’ 2017 financial report.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.